Inhibrx Biosciences, Inc. (INBX)
| Market Cap | 1.33B +13.9% |
| Revenue (ttm) | n/a +550.0% |
| Net Income | -138.18M |
| EPS | -8.88 |
| Shares Out | 14.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,191 |
| Open | 92.38 |
| Previous Close | 90.61 |
| Day's Range | 89.30 - 93.48 |
| 52-Week Range | 57.30 - 155.29 |
| Beta | 4.04 |
| Analysts | Buy |
| Price Target | 266.67 (+194.73%) |
| Est. Earnings | Nov 24, 2026 |
About INBX
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung canc... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for INBX stock is "Buy." The 12-month stock price target is $266.67, which is an increase of 194.73% from the latest price.
News
Inhibrx Announces Participation in Upcoming Scientific Conferences
SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of nov...
Inhibrx director buys $500K in common stock
In a regulatory filing, Inhibrx (INBX) disclosed that its director Jon Kayyem bought 5K shares of common stock on September 23 in a total transaction size of $500K. Published first…
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
Inhibrx Biosciences Transcript: Study update
INBRX-106 plus pembrolizumab showed significant improvements in response rates, depth, and durability in first-line HNSCC, especially in HPV-positive patients, with manageable safety. Expansion of the study and accelerated regulatory strategies are planned, with broad potential across immunogenic tumors and vaccine combinations.
Inhibrx Biosciences Press release: Study update
Inhibrx Biosciences issued a press release on September 8, 2026, disclosing material business information to investors.
Inhibrx Biosciences Slides: Study update
Inhibrx Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study
Inhibrx (INBX) Biosciences announced the primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a…
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 2...
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.
Inhibrx initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Inhibrx (INBX) with a Buy rating and $245 price target Inhibrx is a clinical-stage biotechnology company that is advancing ozekibar and INBRX-106, the analyst tel...
Inhibrx Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical co...
Inhibrx Biosciences Quarterly report: Q2 2026
Inhibrx Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Inhibrx Biosciences Earnings release: Q2 2026
Inhibrx Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeu...
Inhibrx announces FDA acceptance of BLA for ozekibart
Inhibrx (INBX) Biosciences announced that the U.S. FDA has accepted for filing its Biologics License Application seeking approval of ozekibart for the treatment of patients with unresectable or metast...
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventio...
Inhibrx price target raised to $325 from $300 at Stifel
Stifel raised the firm’s price target on Inhibrx (INBX) to $325 from $300 and keeps a Buy rating on the shares.
Inhibrx Reports First Quarter 2026 Financial Results
SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical comp...
Inhibrx Biosciences Quarterly report: Q1 2026
Inhibrx Biosciences has published its Q1 2026 quarterly earnings report on May 14, 2026.
Inhibrx’s INBRX-106 shows potential benefit in HNSCC
Inhibrx (INBX) Biosciences announced positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavale...
Inhibrx Biosciences Transcript: Study update
Interim phase II data show INBRX-106 plus pembrolizumab achieved a 44% ORR versus 21.4% for pembrolizumab alone in first-line PD-L1-positive head and neck cancer, with deeper and more complete responses and a manageable safety profile. Robust T cell activation supports further phase III development.
Inhibrx Biosciences Press release: Study update
Inhibrx Biosciences issued a press release on May 11, 2026, disclosing material business information to investors.
This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.
Inhibrx Biosciences releases positive preliminary results from its trial of a new head and neck cancer treatment.
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab com...
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT – SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage bio...